EFTR - Effector Therapeutics Inc logo

Effector Therapeutics Inc

EFTR
Net income grew 100% of yearsRevenue grew 100% of years1Y
Compare EFTR Hold

eFFECTOR Therapeutics develops targeted cancer therapies, including Zotatifin for solid tumors and Tomivosertib for metastatic non-small cell lung cancer. Its research focuses on selective translation regulator inhibitors and collaborations with Pfizer.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth3.30%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendGrew
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-319.20%
Net Trend33%
Net Income Consistencyโ€”
Rev Growth-88.67%
Rev Trend67%
Revenue Consistencyโ€”

Explore the 2021 public Archive ranking โ†’

Where Effector Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. EFTR does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-08
$ 0.00โ€”
5 Years2021-10-08
$ 296.00-100.00%
All Time2021-08-26
$ 15.21-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 162K-$ 34M$ 25M
2023$ 0.00-$ 35M$ 18M
2022$ 3M-$ 12M$ 26M
IPO2021$ 1M$ 15M$ 49M

Membership

Explore EFTR with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,126 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies